Medicare Benefits Schedule - Item 16015

Administration of Strontium 89 for the relief of bone pain due to skeletal metastases (as indicated by a positive bone scan), if systemic antineoplastic therapy is unavailable or has failed to control the patient’s disease and either:

a) the disease is poorly controlled by conventional radiotherapy; or

b) conventional radiotherapy is inappropriate, due to the wide distribution of sites of bone pain.

Fee: $4,766.15 Benefit: 75% = $3,574.65 85% = $4,661.65

(See para TR.3.1 of explanatory notes to this Category)

• Previous - Item 16012
• Next - Item 16018

Medicare benefits for items in Group T3 are only payable when the service is provided by a specialist or consultant physician with training in nuclear medicine.

Related Items: 16003 16006 16009 16012 16015 16018 16050 16055 16060